10x Science
Winter 2026 NewThe AI-native platform for next-generation protein characterization.
10x Science develops frontier AI models with deep memory to redefine how scientists understand and engineer biology across the life sciences, starting with drug development. AI-powered drug discovery is flooding the pipeline with new candidates faster than ever. But before any of them can advance to the clinic, scientists must deeply characterize the protein therapeutic to understand whether it will work. Today, that process takes months of manual, error-prone analysis that cannot keep pace with discovery. Our AI-native platform automates it, giving drug developers the confidence to advance the right candidates and stop the wrong ones early. We have strong commercial traction with enterprise pharma customers. Our founding team built the field of next-generation protein characterization out of Carolyn Bertozzi's Nobel laureate lab at Stanford. Collectively, we have 18+ years of collective domain expertise, 47+ scientific publications, and a 2x YC Founder. We move at the highest velocity and are positioned to lead the next generation of modern AI development in the life sciences.
AI Investor Summary
10x Science is building an AI-native platform to accelerate drug discovery by providing next-generation protein characterization. Their frontier AI models with deep memory aim to solve the critical bottleneck of analyzing therapeutic candidates, which currently takes months manually. Led by a world-class scientific and entrepreneurial team, they are poised to redefine how biology is understood and engineered.
Key Highlights
- ● Exceptional founding team with deep scientific expertise and proven entrepreneurial track record.
- ● Addresses a critical bottleneck in the rapidly growing AI-driven drug discovery market.
- ● Strong academic pedigree with direct ties to Nobel laureate research.
Risk Factors
- ● Execution risk in translating cutting-edge AI research into a robust, scalable B2B product.
- ● Long sales cycles and adoption challenges within traditional pharmaceutical R&D organizations.
- ● Competition from established players and other AI startups in the drug discovery space.
Founders
Chemistry postdoc and Damon Runyon Cancer Research Fellow in Prof. Carolyn Bertozzi's lab (2022 Nobel Prize in Chemistry) at Stanford University. Next-generation scientific leader in chemical biology and glycobiology with 1500+ citations & h-index 22. Received my B.S. double major in chemistry & mathematics at UC San Diego (2016) and Ph.D. in materials chemistry & analytical chemistry at the University of Wisconsin-Madison (2023).
Previously received my B.S. in Biology from UNC-Chapel Hill. I then joined Dr. Steven Carr’s Proteomics Platform Lab at the Broad Institute of MIT and Harvard, where I developed new methods in mass spectrometry. I later became a Ph.D. student and NSF-GRFP fellow in the Department of Biology at Stanford University, where I was co-advised by Dr. Carolyn Bertozzi (2022 Nobel Laureate in Chemistry) and Dr. Or Gozani.
I am a 2x YC Founder. Previously, I built AI for go-to-market teams as the 2nd hire and founding engineer at Nooks. Then, I forward deployed myself in research labs at the University of Washington, UCSF, and Stanford, where I was mentored by world-renowned scientists in analytical chemistry and cancer research. In < 1 year, I published 2 papers and won 4 national awards. Now, I'm building ultrafast AI models for drug discovery teams to characterize proteins and pharmaceutical candidates.
Score Breakdown
Exceptional technical depth and domain expertise. David Roberts brings world-class chemical biology and glycobiology credentials, including mentorship from a Nobel laureate and significant publication record. Andrew Reiter's background in proteomics and mass spectrometry from the Broad Institute and Stanford is highly relevant. Vishnu Tejus is a proven repeat founder with strong AI/ML engineering experience from Google and Microsoft, and prior YC experience. This is a highly synergistic and credentialed team. [Boost +3: PhD from Stanford; PhD from Stanford; Founder from Google; PhD from Stanford]
The market for drug discovery and development is massive and growing, with significant tailwinds from AI acceleration. The need for faster, more accurate protein characterization is a critical bottleneck. While competitive, the timing is ripe for a disruptive AI-native solution. TAM is substantial, likely in the tens of billions globally. [Boost +0.5: Hot sector: ai]
The core concept of AI-native protein characterization with deep memory is technically differentiated and addresses a clear pain point. The promise of 'explainable AI' is a strong selling point for scientific adoption. Defensibility will hinge on the proprietary nature of their AI models and the data they generate. UX quality is TBD at this stage but crucial for adoption by busy scientists.
Early stage with a recent $4.8M seed round, which is a positive signal of investor interest. No specific user or revenue numbers are provided, making it difficult to assess growth beyond initial funding. Partnerships and press coverage are positive but standard for a seed-stage company raising capital. [Boost +3: Tier-1 VC: accel; Tier-1 VC: accel; Tier-1 VC: accel; Major press: techcrunch]
News
10x Science has closed a $4.8 million seed funding round, led by Initialized Capital, to advance its AI platform for molecular-level protein characterization, addressing a key bottleneck in drug development.
10x Science has secured $4.8 million in seed funding to deploy an AI-powered platform that efficiently characterizes and prioritizes drug candidates, addressing the bottleneck created by AI-driven drug discovery.
10x Science, a spinout from a Stanford lab, has secured $4.8 million in seed funding to develop AI-native software that automates protein characterization for biologics drug developers.
10x Science has secured $4.8 million in seed funding, led by Initialized Capital, to develop an AI platform for molecular-level protein characterization in the life sciences, aiming to accelerate drug development.
10x Science has closed a $4.8 million seed funding round, led by Initialized Capital, to advance its AI platform for automated and explainable molecular protein characterization, aiming to speed up drug development.
Startup 10x Science has raised $4.8 million in seed funding to use AI agents for automating the characterization of drug candidates, addressing a significant bottleneck in drug discovery.
10x Science, a Y Combinator W26 startup, has raised $4.8 million in a seed funding round to develop AI models for understanding and engineering biology, starting with drug development.
10x Science announced the closing of its $4.8M seed round led by Initialized Capital, with participation from Y Combinator and others, to develop AI for molecular-level protein characterization in the life sciences.
10x Science has secured $4.8 million to develop an AI platform that aims to automate and accelerate the molecular-level characterization of proteins, a critical step in drug development.
10x Science has secured $4.8 million in seed funding to develop an AI platform that addresses the bottleneck in characterizing potential drug candidates derived from AI-driven discovery.
10x Science is building an AI-native platform for protein characterization to accelerate drug development by automating data analysis and providing faster, more accurate insights.
10x Science, a company developing AI for molecular-level protein characterization, has closed a $4.8 million seed funding round led by Initialized Capital, with participation from Y Combinator and others.
10x Science has introduced an AI platform designed to significantly speed up the drug development process by improving the characterization of therapeutic proteins.
10x Science raised a Seed round of $500K from Y Combinator on January 1, 2026.
10x Science is building an AI-native platform to automate protein characterization, aiming to make drug development ten times faster by reducing analysis time from weeks to minutes.
10x Science, a Y Combinator Winter 2026 startup, has launched its AI-native platform to accelerate therapeutic protein characterization, addressing the bottleneck in drug development.
10x Science has launched an AI-native platform designed to accelerate the characterization of therapeutic proteins, aiming to overcome a significant bottleneck in drug development.
10x Science is developing an AI-native platform to automate and speed up protein characterization, a critical but slow stage in biopharmaceutical development, enabling faster translation of AI-discovered drug candidates.
Quick Info
- Batch
- Winter 2026
- Team Size
- 3
- Location
- San Francisco, CA, USA
- Founders
- 3
- Scraped
- 4/10/2026